KENILWORTH, N.J.–RDx BioScience (RDx), providers of high-quality laboratory and genomic testing and evidence-based research designed to direct patient care for clinicians, employers and payers, announces today its appointment of Eric W. Johnson, Ph.D., as director of Laboratory Services, and Ashley Kiley, MPH, chair, Industry Advisory Committee and board member, New York Pain Society, as director of Provider Relations. RDx Chief Medical Officer Scott Howell, DO, MPH&TM, CPE, emphasizes that these respected professionals advance RDx’s mission to further empower physicians, collaborate with providers, and establish prescriber best practices.
“A preeminent scientist in the field, Dr. Johnson brings nearly two decades of clinical laboratory experience overseeing full-service Molecular Diagnostic testing nationwide,” says Dr. Howell. “Highly regarded for his work focused on ensuring ethical, compassionate community-based access to rare disease genetic testing, Dr. Johnson oversaw the Neurovascular / Epilepsy Genetics Gene Discovery Research Laboratory, and played a key role in establishing and mentoring BioBanking efforts for a number of rare disease family groups.”
Dr. Johnson has authored numerous manuscripts relating to neuroscience and genetics, co-discovered the nature, identity and function of several epilepsy and neurovascular-related genes, and is an esteemed expert in translational research: moving genetic tests for rare diseases from the lab bench to the clinic.
Dr. Howell also points to Kiley’s education, expertise and in-depth knowledge of pain management as it relates to the utilization of opioids, saying, “Kiley’s education and robust background in this industry make her eminently qualified to provide physicians with the most thoughtful approach to their practice needs. She is passionate about ensuring that prescriber education initatives begin to take hold across the country.”
Kiley earned a Master of Public Health, magna cum laude, Hunter College School of Public Health, an authored “Policy Suggestions,” a thesis to highlight ways that opioid prescribing can lead to physiological dependency, addiction and misuse.
RDx is a full-service, high-technology laboratory. We are fast, accurate, and deliver value-based service nationally. RDx is accredited by the College of American Pathologists (CAP) as a certified, full-service medical laboratory. Visithttps://www.rdxbioscience.com/
CPR for RDx BioScience
Brittany Tedesco, 201.641.1911 x14